Analyst Price Targets — CPRX
Latest News for CPRX
Aptorum Group (NASDAQ: APM - Get Free Report) and Catalyst Pharmaceuticals (NASDAQ: CPRX - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk. Risk and Volatility Aptorum Group has a beta
The mean of analysts' price targets for Catalyst (CPRX) points to a 28.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Shares of Catalyst Pharmaceuticals, Inc. (CPRX) up 148% since 2022's first outlier institutional inflow signal.
Catalyst (CPRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks offers value investors a better bang for their buck right now?
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CPRX.
U.S. House Trading
No House trades found for CPRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.